Protocol for Researching the Intermediate SARMs Stack:
MK-2866 – For research use only, 1 filled oral syringe daily. Ostarine can be researched for up to 8 weeks.
LGD-4033 – For research use only, 1 filled oral syringe daily. LGD-4033 can be researched for up to 8 weeks. After completion of a cycle, there should be an 8-week break before resuming research.
RAD-140 – For research use only, 1 filled oral syringe daily. RAD-140 can be researched for up to 4 weeks.
PCT – After completion of the cycle, Nolva or Clomid should be used for PCT, at 1 oral syringe per day for 30 days.
Ostarine
GTx Incorporated was founded in Memphis in 1997 and licensed rights to enobosarm from the University of Tennessee Research Foundation; the SARM compounds were invented by James T. Dalton, Duane D. Miller, Karen A. Veverka and their research teams at Ohio State University, the University of Tennessee and GTx, respectively.
By 2007, enobosarm was in a Phase II trial, and that year GTx signed an exclusive license agreement for its SARM program with Merck & Co. The companies ended the deal in 2010.
In August 2011, there was a double-blind, placebo controlled phase II trial that focused on elderly men and postmenopausal women which concluded that Enobosarm showed statistically significant improvements in total lean body mass and physical function without the negative side effects that are normally present with steroids
LGD-4033
According to a clinical trial conducted at the Boston Medical Center’s Section of Endocrinology, Ligandrol can help improve lean body mass and muscle strength.
Another study conducted in January 2013 found that Ligandrol can help increase lean muscle mass, and was generally well tolerated by test subjects.
RAD-140
RAD140 is an investigational selective androgen receptor modulator (SARM) that is developed by Radius Health, Inc. for use in androgen replacement therapy. It was licensed to Ellipses Pharmaceuticals in 2020. Some of the potential benefits under investigation are for the treatment of conditions such as muscle wasting and bone loss.
RAD140 is an investigational selective androgen receptor modulator (SARM) that is developed by Radius Health, Inc. for use in androgen replacement therapy. It was licensed to Ellipses Pharmaceuticals in 2020. Some of the potential benefits under investigation are for the treatment of conditions such as muscle wasting and bone loss.
